{
    "clinical_study": {
        "@rank": "85546", 
        "arm_group": [
            {
                "arm_group_label": "Emervel Lips", 
                "arm_group_type": "Experimental", 
                "description": "Emervel Lips"
            }, 
            {
                "arm_group_label": "Juvederm Ultra Smile", 
                "arm_group_type": "Experimental", 
                "description": "Juvederm Ultra Smile"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to demonstrate the efficacy and safety of Emervel Lips and\n      Juvederm Ultra smile"
        }, 
        "brief_title": "Safety and Efficacy of Lip Injections With Emervel Lips and Juvederm Ultra Smile", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Local Tolerability After Lip Filler Injections", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female subjects aged 18 to 65 years.\n\n          -  Subjects with the intention to undergo lip augmentation treatment.\n\n          -  Subjects treatment-na\u00efve for lip augmentation treatment\n\n          -  Subjects with lip appearance judged by the treating investigator to be suitable for\n             lip line treatment\n\n          -  Subjects with signed informed consent.\n\n        Exclusion Criteria:\n\n          -  Concomitant anticoagulant therapy and therapy with inhibitors of platelet aggregation\n             (e.g. aspirin or other nonsteroidal anti-inflammatory drugs [NSAIDs]), Omega-3 or\n             vitamin E within 10 days before study treatment, or a history of bleeding disorders.\n\n          -  Prior surgery or tattoo to the upper or lower lip or lip line.\n\n          -  Presence of any abnormal lip structure, such as a scar or lump or severe lip\n             asymmetry.\n\n          -  Previous tissue augmenting therapy in the lip area (including oral commissures,\n             marionette and perioral lines) with HA or collagen filler, or laser treatment, within\n             12 months before study entry.\n\n          -  Permanent implant or treatment with non-HA or non-collagen filler in the area\n             surrounding the lips (including nasolabial folds, oral commissures, marionette and\n             perioral lines).\n\n          -  History of herpes labialis with an outbreak within 4 weeks of study entry or with 4\n             or more outbreaks in the 12 months before study entry.\n\n          -  Active skin disease, inflammation or related conditions, such as infection, psoriasis\n             and herpes zoster near or on the area to be treated.\n\n          -  History of angioedema.\n\n          -  Previous hypersensitivity to HA.\n\n          -  Previous hypersensitivity to lidocaine or other amide-type anaesthetics\n\n          -  Cancerous or precancerous lesions in the area to be treated.\n\n          -  Immunosuppressive therapy, chemotherapy, treatment with biologics or systemic\n             corticosteroids within 3 months before study treatment.\n\n          -  Pregnancy or breast feeding.\n\n          -  Participation in any other clinical study within 30 days before inclusion.\n\n          -  Other condition preventing the subject to entering the study in the investigator's\n             opinion, e.g. subjects not likely to avoid other facial cosmetic treatments below the\n             level of the lower orbital rim, subjects anticipated to be unreliable or incapable of\n             understanding the study assessment or unrealistic expectations of treatment result.\n\n          -  Study staff or close relative to study staff (e.g. parents, children, siblings or\n             spouse)."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01745250", 
            "org_study_id": "05DF1210"
        }, 
        "intervention": [
            {
                "arm_group_label": "Emervel Lips", 
                "description": "Lip treatment of both upper and lower lip", 
                "intervention_name": "Emervel Lips", 
                "intervention_type": "Device", 
                "other_name": "Emervel Lips"
            }, 
            {
                "arm_group_label": "Juvederm Ultra Smile", 
                "description": "Lip treatment of both upper and lower lip", 
                "intervention_name": "Juvederm Ultra Smile", 
                "intervention_type": "Device", 
                "other_name": "Juvederm Ultra Smile"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "lip", 
            "fillers", 
            "Hyaluronic acid"
        ], 
        "lastchanged_date": "May 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dusseldorf", 
                    "country": "Germany"
                }, 
                "name": "Medical Skin center"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Evaluator-blinded, Comparative Study of the Safety and Efficacy of Lip Injections With Emervel Lips and Juvederm Ultra Smile", 
        "overall_official": {
            "affiliation": "Medical Skin Center", 
            "last_name": "Said Hilton, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To assess local tolerability after treatment including erythema, bruising, itching, swelling, pain/ tenderness at 14 days. Number of subjects reporting the events will be analysed.", 
            "measure": "Local tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01745250"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate long-term safety throughout the study period", 
                "measure": "AE reporting", 
                "safety_issue": "Yes", 
                "time_frame": "24 weeks"
            }, 
            {
                "description": "To evaluate esthetic change of lips from baseline using GEIS", 
                "measure": "Global Aesthetic Improvement Scale (GAIS)", 
                "safety_issue": "No", 
                "time_frame": "Week 2 to week 24"
            }, 
            {
                "description": "To evaluate esthetic change of lips from baseline using LFGS", 
                "measure": "Lip Fullness Grading Scale (LFGS)", 
                "safety_issue": "No", 
                "time_frame": "0-24 weeks"
            }, 
            {
                "description": "To evaluate subjects satisfaction in terms of a subject satisfaction questionnaire", 
                "measure": "Subject's satisfaction", 
                "safety_issue": "No", 
                "time_frame": "0-24 weeks"
            }
        ], 
        "source": "Q-Med AB", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Q-Med AB", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}